Your browser doesn't support javascript.
loading
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Slamon, Dennis J; Fasching, Peter A; Hurvitz, Sara; Chia, Stephen; Crown, John; Martín, Miguel; Barrios, Carlos H; Bardia, Aditya; Im, Seock-Ah; Yardley, Denise A; Untch, Michael; Huang, Chiun-Sheng; Stroyakovskiy, Daniil; Xu, Binghe; Moroose, Rebecca L; Loi, Sherene; Visco, Frances; Bee-Munteanu, Valerie; Afenjar, Karen; Fresco, Rodrigo; Taran, Tetiana; Chakravartty, Arunava; Zarate, Juan Pablo; Lteif, Agnes; Hortobagyi, Gabriel N.
Affiliation
  • Slamon DJ; David Geffen School of Medicine at UCLA, 10945 Le Conte Ave. Suite 3360, Los Angeles, CA 90095, USA.
  • Fasching PA; University Hospital Erlangen Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Hurvitz S; University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Chia S; British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Crown J; St. Vincent's Hospital, Dublin, Ireland.
  • Martín M; Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain.
  • Barrios CH; Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
  • Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Im SA; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Yardley DA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA.
  • Untch M; Interdisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin, Germany.
  • Huang CS; National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, Taiwan.
  • Stroyakovskiy D; Moscow City Oncology Hospital No. 62 of Moscow Healthcare Department, Moscow Oblast, Russia.
  • Xu B; Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Moroose RL; Orlando Health Cancer Institute, Orlando, FL, USA.
  • Loi S; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Visco F; National Breast Cancer Coalition, Washington, DC, USA.
  • Bee-Munteanu V; TRIO - Translational Research in Oncology, Paris, France.
  • Afenjar K; TRIO - Translational Research in Oncology, Paris, France.
  • Fresco R; TRIO - Translational Research in Oncology, Montevideo, Uruguay.
  • Taran T; Novartis Pharma AG, Basel, Switzerland.
  • Chakravartty A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Zarate JP; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Lteif A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ther Adv Med Oncol ; 15: 17588359231178125, 2023.
Article in En | MEDLINE | ID: mdl-37275963
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Guideline / Prognostic_studies Language: En Journal: Ther Adv Med Oncol Year: 2023 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Guideline / Prognostic_studies Language: En Journal: Ther Adv Med Oncol Year: 2023 Type: Article Affiliation country: United States